VITAL is an accelerator hub in the U.S. Biomedical Advanced Research and Development Authority (BARDA) Accelerator Network. The BARDA Accelerator Network fosters growth of the global health security innovation ecosystem by supporting early-stage companies to overcome their business, marketing, and operational hurdles. VITAL supports development of innovative therapeutics solutions in alignment with BARDA’s mission to promote health security, and is managed and operated by Start2 Group.
Four pillars of support, one mission: Helping innovators turn promising science into health security solutions.
Explore active funding opportunities, prizes, and programs designed to advance breakthrough therapeutics aligned with BARDA’s health security mission.
Are you working on broad-spectrum small molecule antiviral therapies? VITAL seeks submissions for the SMART Antiviral Prize to fund breakthrough antiviral approaches with activity against members of the Togaviridae and Flaviviridae families – which include dengue, Zika, West Nile, and chikungunya – that have the potential to advance into clinical trials and achieve U.S. regulatory approval.
Drug repurposing is one of the fastest and most cost-effective pathways for developing therapeutic medical countermeasures (MCMs).
VITAL and BARDA seek to bring together complementary capabilities across the scientific and technology communities to establish platforms that can rapidly identify and evaluate promising therapeutic candidates, including repurposed drugs, repositioned drugs, natural products, and combination therapies, for emerging national health security threats.
BARDA and VITAL seek innovative mucosal vaccine approaches for influenza. The program will support preclinical evaluation of vaccine technologies focused on eliciting a robust, durable, and protective mucosal and systemic immune response.
Proposed vaccine technologies may include innovations in: novel formulations, delivery systems, mucosal adjuvants, antigen-adjuvant co-delivery, and enabling/integrated platform technologies. Although influenza is the initial use case, these platform technologies should be translatable to other respiratory pathogens.
Are you working on groundbreaking therapeutics solutions? The VITAL Hub seeks proposals for the development of innovative therapeutics solutions in alignment with BARDA’s mission to promote health security. Multi-use/platform technologies are preferred for this solicitation. VITAL invites startups and university-backed projects to apply for non-dilutive funding of up to $250K.
Established by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
The BARDA Accelerator Network fosters the growth of health security innovation ecosystems globally and accelerates the development and commercialization of next-generation health security solutions.
